


RealRate

## PHARMACEUTICAL 2018

**EMERGENT** 

## Emergent BioSolutions Inc. Rank 17 of 349





## PHARMACEUTICAL 2018





## Emergent BioSolutions Inc. Rank 17 of 349

The relative strengths and weaknesses of Emergent BioSolutions Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Emergent BioSolutions Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 416% points. The greatest weakness of Emergent BioSolutions Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 218%, being 496% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	485,389
Cost of Goods Sold	0
Intangible Assets	168,727
Liabilities, Current	100,068
Liabilities, Non-Current	18,132
Other Assets	8,880
Other Compr. Net Income	633
Other Expenses	231,746
Other Liabilities	39,661
Other Net Income	-5,652
Property and Equipment	407,210
Research and Development	97,384
Revenues	560,873
Selling, General and Administrative Expense	143,497

Output Variable	Value in 1000 USD
Assets	1,070,206
Liabilities	157,861
Expenses	472,627
Stockholders Equity	912,345
Net Income	82,594
Comprehensive Net Income	82,910
Economic Capital Ratio	218%